

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(193) Ferritin					22							19	18	95%
Samples and groups	[µg/L]													
Sample A		146	29	20	22							19	19	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		168	29	17	6	0	CVPG	171	3,3	24%	129	213	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		114	3,4	3,0	5	0	CVPG	117	3,3	24%	88,9	146	5	
Other					11	0							8	
								4x 4/60, 1x 4/149, 2x 4/179, 1x 6/1, 1x 6/60, 1x 6/177, 1x 6/178						
Sample B		120	30	25	22							19	18	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		149	16	11	6	0	CVPG	138	3,6	24%	104	172	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		88,7	17	19	5	0	CVPG	90,4	3,2	24%	68,7	113	5	
Other					11	0							8	
								4x 4/60, 1x 4/149, 2x 4/179, 1x 6/1, 1x 6/60, 1x 6/177, 1x 6/178						
(320) LH					16							16	14	88%
Samples and groups	[U/L]													
Sample A		8,88	2,0	23	16							16	14	88%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		7,95	0,67	8,4	8	0	CVPG	7,92	0,14	15%	6,73	9,11	8	
Other					8	0							8	
								4x 4/1, 4x 4/60						
Sample B		26,3	5,5	21	16							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		23,9	2,6	11	8	0	CVPG	24	0,39	15%	20,4	27,6	8	
Other					8	0							8	
								4x 4/1, 4x 4/60						
(321) FSH					16							16	16	100%
Samples and groups	[U/L]													
Sample A		5,64	0,34	5,9	16							16	16	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		5,88	0,30	5,0	8	0	CVPG	5,92	0,10	15%	5,03	6,81	8	
Other					8	0							8	
								4x 4/1, 4x 4/60						
Sample B		8,63	0,54	6,3	16							16	16	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		8,81	0,73	8,3	8	0	CVPG	8,99	0,13	15%	7,64	10,4	8	
Other					8	0							8	
								4x 4/1, 4x 4/60						
(322) Prolactin					17							16	14	88%
Samples and groups	[mU/L]													
Sample A		318	50	16	17							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		291	17	5,9	9	0	CVPG	299	5,2	16%	251	347	9	
Other					8	0							7	
								1x 1/36, 1x 4/1, 1x 4/29, 4x 4/60, 1x 4/179						
Sample B		164	27	16	17							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		153	8,7	5,7	9	0	CVPG	154	2,5	16%	129	179	9	
Other					8	0							7	
								1x 1/36, 1x 4/1, 1x 4/29, 4x 4/60, 1x 4/179						
(325) Insulin					10							9	9	100%
Samples and groups	[mU/L]													
Sample A		37,0	7,6	21	10							9	9	100%
Other					10	0							9	
								1x 1/36, 4x 4/1, 2x 4/12, 2x 4/60, 1x 4/179						
Sample B		70,6	12	17	10							9	9	100%
Other					10	0							9	
								1x 1/36, 4x 4/1, 2x 4/12, 2x 4/60, 1x 4/179						
(326) Folate					19							19	16	84%
Samples and groups	[nmol/L]													
Sample A		9,96	2,2	22	19							19	17	89%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		11,2	0,30	2,6	6	0	CVPG	10,8	0,24	27%	7,88	13,8	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,42	2,0	23	6	0	CVPG	7,43	0,13	27%	5,42	9,44	6	
Other					7	0							7	
								4x 4/1, 1x 4/149, 2x 4/179						
Sample B		10,0	2,7	27	19							19	17	89%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		11,4	0,55	4,8	6	0	CVPG	11,2	0,24	27%	8,17	14,3	6	

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(326) Folate					19							19	16	84%
Samples and groups	[nmol/L]													
Sample B		10,0	2,7	27	19							19	17	89%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,32	1,9	23	6	0	CVPG	7,48	0,13	27%	5,46	9,5	6	
Other					7	0							7	
								4x 4/1, 1x 4/149, 2x 4/179						
(327) Vitamin B12					19							19	18	95%
Samples and groups	[pmol/L]													
Sample A		241	51	21	19							19	18	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		190	17	9,0	6	0	CVPG	182	4,4	20%	145	219	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		289	26	9,0	6	0	CVPG	273	2,2	20%	218	328	6	
Other					7	0							7	
								4x 4/1, 1x 4/149, 2x 4/179						
Sample B		652	98	15	19							19	18	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		550	18	3,3	6	0	CVPG	543	9,2	20%	434	652	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		715	59	8,2	6	0	CVPG	688	3,9	20%	550	826	6	
Other					7	0							7	
								4x 4/1, 1x 4/149, 2x 4/179						
(319) Vitamin B12 (active)					4							0		
Samples and groups	[pmol/L]													
Sample A		65,8	5,9	9,0	4							4	4	100%
Other					4	0							4	
								2x 4/1, 2x 4/60						
Sample B		229	120	51	4							0		
Other					4	0							0	
								2x 4/1, 2x 4/60						
(328) hGH					7							7	7	100%
Samples and groups	[mU/L]													
Sample A		14,8	2,6	17	7							7	7	100%
Other					7	0							7	
								1x 1/36, 3x 4/12, 2x 4/29, 1x 4/60						
Sample B		42,0	5,3	13	7							7	7	100%
Other					7	0							7	
								1x 1/36, 3x 4/12, 2x 4/29, 1x 4/60						
(329) IGF-1					4							3	3	100%
Samples and groups	[µg/L]													
Sample A		706	310	44	4							3	3	100%
Other					4	0							3	
								1x 1/36, 3x 4/29						
Sample B		627	260	42	4							3	3	100%
Other					4	0							3	
								1x 1/36, 3x 4/29						
(390) Renin					2							2	2	100%
Samples and groups	[ng/L]													
Sample A		36,6	5,9	16	2							2	2	100%
Other					2	0							2	
								1x 1/185, 1x 2/66						
Sample B		42,6	6,1	14	2							2	2	100%
Other					2	0							2	
								1x 1/185, 1x 2/66						
(392) IGF-BP3					2							1	1	100%
Samples and groups	[µg/L]													
Sample A		3580	820	23	2							1	1	100%
Other					2	0							1	
								1x 1/183, 1x 4/29						
Sample B		3320	580	17	2							1	1	100%
Other					2	0							1	
								1x 1/183, 1x 4/29						
(393) C-peptide					13							12	10	83%
Samples and groups	[pmol/L]													
Sample A		276	51	19	13							12	11	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		318	10	3,3	6	0	CVPG	317	3,8	20%	253	381	6	
Other					7	0							6	
								1x 1/36, 4x 4/1, 2x 4/179						
Sample B		399	85	21	13							12	10	83%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		460	15	3,2	6	0	CVPG	464	5,9	20%	371	557	6	
Other					7	0							6	
								1x 1/36, 4x 4/1, 2x 4/179						

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(394) SHBG					7							7	7	100%
Samples and groups	[nmol/L]													
Sample A		31,2	3,1	10	7							7	7	100%
Other					7	0						7		
							2x 4/1, 1x 4/12, 2x 4/60, 2x 4/179							
Sample B		34,0	3,4	10	7							7	7	100%
Other					7	0						7		
							2x 4/1, 1x 4/12, 2x 4/60, 2x 4/179							
(405) Parathyroid hormone (PTH)					20							20	18	90%
Samples and groups	[pmol/L]													
Sample A		23,3	3,2	14	20							20	19	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		23,6	1,6	6,6	6	0	CVPG	24,9	0,87	23%	19,1	30,7	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		21,3	2,3	11	9	1	CVPG	20,7	0,33	23%	15,9	25,5	9	
Other					5	0						5		
							2x 4/1, 1x 4/29, 2x 4/179							
Sample B		0,768	0,25	32	20							20	18	90%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		0,760	0,074	9,8	6	0	CVPG	0,796	0,031±0,284	0,52	1,08	6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,747	0,19	25	9	0	CVPG	0,661	0,029±0,276	0,385	0,937	9		
Other					5	0						5		
							2x 4/1, 1x 4/29, 2x 4/179							

st_kn_p

End of report

Printed: 19.05.2021